Skip to content

DR. VROLIX

Active Private limited company (pre-2019)founded 1995active for 31 yearsRichter 20, 3600 GenkKBO/BCE: BE 0456.470.122

Lifetime

24 annual accounts with figures on one time axis, 30 filings since 1996
peak of €1.1m in 2022
€897,337▲ 151%
peak of €867,325 in 2022
€561,157▲ 75.8%
peak of €2.9m in 2025
€2.9m▲ 24.2%
€37,747▼ 95.2%
peak of 0 FTE in 2023
0 FTE 
Board1 name since 1995
1 director
Documentsfilings and deeds
30-09-202661 days late
2025abbreviated format
Gross margin from €357,696 to €897,337Result from €319,145 to €561,157Equity from €2.3m to €2.9mDebts from €783,661 to €37,747Cash from €610,746 to €288,783

Key points

from the 2025 annual accounts

Equity

€2.9m ▲ 24.2%

DR. VROLIX has made a profit in every financial year since 2002.

Result

€561,157 ▲ 75.8%
€319,0002024€561,0002025

The result rose in 2025: mostly from a one-off income of €494,866.

Turnover

≈ €1.4m estimated

The abbreviated format states no turnover.

Liquidity

74.80 was 2.66 in 2024

Short-term debts fell from €783,425 to €37,506.

Filings

30 annual accounts 61 days
AprilJune31 JulyOctober200020102020

Latest accounts filed late: after the legal deadline.

Position in the sector

98.7%

Higher solvency than 95% of companies in human health. The sector median is 59.4%, over 2,825 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,155 companies had the same profile as DR. VROLIX has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,155 companies, not a prediction for DR. VROLIX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager, since 10-11-1995

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0456470122
Capital decrease of €1,748,127.20 to €18,600 The capital fell from €1,766,727.20 to €18,600, cancelling 70,489 shares · reappointed as manager · Gazette deed
Capital increase of €1,748,127.20 to €1,766,727.20 The capital rose from €18,600 to €1,766,727.20, with 70,489 new shares · Gazette deed
Registered office moved to Genk The registered office moved from Vlodropstraat 37 te Genk to Richter 20 te 3600 Genk · General meeting of 17-12-2012 · Gazette deed
All 41 events

Comparable companies

same main activity, similar in size and age
Company
DR. VROLIX Genk €2.9m €897,337 98.7% 0
DOKTERS DEWANDRE-NYSEN Hasselt €2.7m €655,816 94.3% 0
DOKTER KOEN LAGAE Koksijde €2.4m €802,305 74.2% 0
A&E Genk €4.6m €781,629 80.0% 0
MOVENDI Hasselt €3.6m €889,143 82.5% 0.5
DR. BRESSELEERS DIRK - CARDIOLOOG Kapellen €3.0m €757,842 85.5% 0.2
Radioloog Dr. P. BRACKE Kapellen €2.0m €750,770 93.2% 0

These companies have the same main activity as DR. VROLIX: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €2m and €4.6m, founded between 1990 and 2004.

Official details

Source: KBO
Status
Active since 10-11-1995Normal situation
Activity
Specialist medical practiceNACE 86220and 1 other
Financial year end
31 December
Peppol
Reachable since 18-03-2025
Company details

Annual accounts 2025

€2.9m▼ 6.0%
Filing
Filed on 30-09-2026
Financials

Insights on DR. VROLIX

DR. VROLIX files the abbreviated format. That format states no turnover. The gross margin rose from €346,522 in 2002 to €897,337 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DR. VROLIX

What is the company number of DR. VROLIX?
The company number of DR. VROLIX is 0456.470.122. The VAT number is the same number with BE in front: BE 0456.470.122.
Where is DR. VROLIX based?
The registered office is at Richter 20, 3600 Genk.Company details
What does DR. VROLIX do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of DR. VROLIX?
DR. VROLIX is a private limited company (pre-2019) (BVBA).
When was DR. VROLIX founded?
DR. VROLIX was founded on 10-11-1995.
Is DR. VROLIX still active?
Yes, DR. VROLIX is an active enterprise in the KBO register.
What is the turnover of DR. VROLIX?
The turnover in financial year 2025 is about €1.4m. This figure is estimated from the gross margin of €897,337 and 31 comparable companies (NACE 86220). It probably lies between €1.2m and €1.9m.Financials
Is DR. VROLIX profitable?
In financial year 2025, DR. VROLIX made a profit of €561,157.
Where can I find the annual accounts of DR. VROLIX?
DR. VROLIX filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. VROLIX due?
DR. VROLIX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.